1132817-32-3

Basic information

• Product Name: 2-{3-[4-(5-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,4-diazaspiro[4.4]non-3-en-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide
• Synonyms: 2-{3-[4-(5-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,4-diazaspiro[4.4]non-3-en-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide
• CAS NO: 1132817-32-3
• Molecular Weight: 495.504
• Mol File: 1132817-32-3.mol

Chemical Properties

• CAS DataBase Reference: 2-{3-[4-(5-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,4-diazaspiro[4.4]non-3-en-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{3-[4-(5-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,4-diazaspiro[4.4]non-3-en-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide(1132817-32-3)
• EPA Substance Registry System: 2-{3-[4-(5-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,4-diazaspiro[4.4]non-3-en-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide(1132817-32-3)

Safety Data

• Hazardous Substances Data: 1132817-32-3(Hazardous Substances Data)

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 
• 98-16-8 3-trifluoromethylaniline 
• 167024-66-0 2-amino-2-(4-bromophenyl)acetonitrile 
• 950651-29-3 3-(4-bromophenyl)-1,4-diazaspiro[4.4]nonan-2-one 
• 1132817-67-4 3-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,4-diazaspiro[4.4]non-3-en-2-one 
• 351-38-2 N-chloroacetyl-3-(trifluoromethyl)aniline 
• 1132817-68-5 3-[4-(5-methyl-1H-imidazol-1-yl)phenyl]-1,4-diazaspiro[4.4]non-3-en-2-one 
• 25625-57-4 2-bromo-N-(3′-(trifluoromethyl)phenyl)acetamide 

Relevant articles and documents

An efficient and scalable synthesis of the spirocyclic glycine transporter inhibitor GSK2137305

An efficient and scalable synthesis of a glycine transporter inhibitor is presented. The key steps in the synthetic sequence are the formation of a spirocyclic imidazolidinone from an -amino nitrile and a cyclic ketone and an arylation of 4-methyl imidazo

SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER

Compounds of formula (I) and salts thereof are provided: formula (I), wherein the groups are as defined in the specification. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.